EN DE
Watch Hester Biosciences Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Hester Biosciences Limited (HESTERBIO) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Hester Biosciences Limited stock ₹2,009, price ₹2,306, that is 12.9% below the price, quality 64 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE782E01017

HB Hester Biosciences Limited logo Broad data Nov 14, 2026

Hester Biosciences Limited

HESTERBIO · NSE

Expensive (fair value 13% below the price), but solid company and rising price: meets 2 of 3 rules.

Get notified free when this changes
Quality 64/100 
Rising price (uptrend) 
Healthy Growth (revenue 5y +9.2 %/yr in INR) 
Highly profitable · 41.6% net margin (TTM) 
Low debt 
Generates free cash flow 
0.5% dividend yield · Well covered
Broad data 
Mixed vs. peers (6/14) 
Wide moat 69/100 · thin data
Revenue last quarter 8% below a year ago. 
Fair value ₹2,009 · Overvalued 
Quality growth
Watch Hester Biosciences Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹3,180 ₹1,245 Fair Value ₹2,009 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range ₹1,245 – ₹3,180 · fair‑value band ₹1,062 – ₹3,114 · the ₹2,306 price screens above the ₹2,009 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Hester Biosciences in your weekly email

Every Wednesday you see whether Hester Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hester Biosciences Limited manufactures and trades in veterinary vaccines and health products in India and internationally. It operates through two segments, Poultry Healthcare and Animal Healthcare.

Show moreShow less

The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis.

It also offers vaccines for peste des petits ruminants, goat pox, brucella, lumpy skin disease, contagious bovine pleuropneumonia, and contagious caprine pleuropneumonia for cattle, buffalo, sheep, and goats; and diagnostic services.

In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutics, nutritional supplements, and specialised formulations to enhance animal wellness and productivity.

Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, grooming products, and anti-infective formulations; and healthcare products, such as immune boosters, gut health enhancers, farm hygiene, vitamins, minerals, and specialty feed supplements for critical needs comprising disease prevention, growth, and nutritional balance.

Additionally, the company provides Silvectant, a hydrogen peroxide and silver nitrate solution for disinfection of poultry sheds; Hestbac, a probiotic supplement to control pathogenic bacteria; Hestflora, a combined probiotic and prebiotic formulation that supports gut health and performance; AmmoStop, a probiotic blend for odour control and respiratory comfort in poultry farms.

It also offers INACTIVATED H9N2 vaccine for low pathogenic avian influenza; ICEFT RTU, a ceftiofur formulation for uterine and bacterial infections; and Inomilk Gel, an oral calcium supplement, as well as operates diagnostic labs for poultry.

Hester Biosciences Limited was incorporated in 1987 and is headquartered in Mehsana, India.

Stock analysis

Hester Biosciences Limited (HESTERBIO) currently trades at ₹2,306, while our model-based Fair Value estimate is ₹2,009, 13% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹1,339 per share, and 0 of the 26 models we run sit above the ₹2,306 price.

Bear case: the Asset-Based group reads lowest at ₹276.06, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: ₹1,062 (bear) to ₹3,114 (bull), the price of ₹2,306 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Hester Biosciences Limited reported revenue of ₹3.3B in FY2026 versus ₹2.4B in FY2022, a compound +9.1%/yr. Reported net income was ₹556M in FY2026, compounding +9.1%/yr from FY2022.

Key figures

Market cap ₹21.1B (≈ $224M) Micro · P/E ratio 13.4 · P/S ratio 6.44 · EPS (TTM) ₹160.95 · Dividend yield 0.5% · Net margin 41.6% · Return on equity 16.6% · Return on assets (EBIT) 10.1% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 69 out of 100 (low confidence).

What moves the price

The share trades about 9% below its 52-week high and 84% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −13%, HESTERBIO screens cheaper than that median.

Fair Value models

Bear ₹1,062 Fair Value ₹2,009 Bull ₹3,114
Price ₹2,306 · Downside -12.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹94.49 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF ₹399.37 ₹691.87 ₹1,106 79
Growth DCF ₹386.92 ₹632.04 ₹950.51 77
Residual Income ₹371.34 ₹425.74 ₹587.79 76
All 26 models by family
DCF Models
FCF DCF ₹399.37 ₹691.87 ₹1,106 79
Owner Earnings ₹236.15 ₹433.52 ₹713.11 74
5Y Revenue Exit ₹512.53 ₹992.51 ₹1,652 70
5Y EBITDA Exit ₹663.04 ₹1,308 ₹2,131 73
5Y P/E Exit ₹667.95 ₹1,319 ₹2,076 69
10Y Revenue Exit ₹433.45 ₹816.03 ₹1,412 64
10Y EBITDA Exit ₹531.20 ₹1,004 ₹1,741 66
10Y P/E Exit ₹533.85 ₹1,010 ₹1,703 62
Earnings-Based
Graham-Dodd ₹444.75 ₹2,209 ₹3,047 64
Lynch FV ₹632.02 ₹902.88 ₹1,174 61
PEG = 1.0 ₹632.02 ₹902.88 ₹1,174 57
EPV ₹276.00 ₹316.99 ₹349.64 74
Dividend Discount
Gordon GGM ₹45.14 ₹71.86 ₹89.92 69
DDM Multi-Stage ₹45.14 ₹69.85 ₹77.62 67
Multiples
P/E Multiple ₹1,079 ₹1,439 ₹1,799 63
P/S Multiple ₹833.91 ₹1,112 ₹1,390 58
P/B Multiple ₹1,391 ₹1,854 ₹2,318 55
EV/EBIT ₹790.10 ₹1,129 ₹1,467 65
EV/EBITDA ₹843.89 ₹1,200 ₹1,557 67
EV/Revenue ₹499.30 ₹810.02 ₹1,121 53
Asset-Based
NCAV (Graham) ₹206.02 ₹276.06 ₹412.04 54
Growth DCF
Growth DCF ₹386.92 ₹632.04 ₹950.51 77
Rev-Margin DCF ₹512.53 ₹978.08 ₹1,591 70
Economic Profit
Residual Income ₹371.34 ₹425.74 ₹587.79 76
ROIC Compounder ₹276.00 ₹316.99 ₹349.64 72
Growth Earnings
Growth-Adj P/E ₹937.00 ₹1,339 ₹1,740 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 64/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 52
How much profit the company makes from its sales and capital
Quality Growth 57
Are margins and returns getting better?
Cashflow 55
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 69
Does it invest with discipline instead of growing at any price?
Low Volatility 70
How calm the share price moves, does not count
Price momentum 62
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 79
Distance to the 52-week high, does not count
New shares 79
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 89/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+6.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
Start year 2021 (pandemic). Over 10 years: +12.7% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.1%
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+4.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.1%
Dividend (yield on the price)0.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.10.8% vs 11.8%, steady
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → 20%
2026 sits 116% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2021 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+37.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +32.4% a year for the price.

HESTERBIO screens overvalued: fair value 13% below the price. Compare with Merck KGaA →

Compare Hester Biosciences Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 64 · Top 25%
Fair Value upside −12.9% · Below median
Profitability
Return on equity (12 months) 16.6% · Top 25%
Return on assets 8.2% · Top 25%
Net margin (12 months) 41.6% · Top 25%
Operating margin (12 months) 20.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −8.2% · Below median
Dividend yield (12 months) 0.5% · Bottom 25%
Balance sheet
Debt / equity 0.25× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 13.4× · Cheaper than median
P/B 5.85× · Priciest 25%
P/S (12 months) 6.44× · Priciest 25%
Price / free cash flow (fiscal year) 50.5× · Priciest 25%
EV/EBITDA 27.7× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)16 · sector 19
FUTURE (revenue growth)0 · sector 29
PAST (return on equity)66 · sector 26
HEALTH (low debt)88 · sector 96
DIVIDEND (yield)10 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hester Biosciences Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Hester Biosciences Limited Fair Value". https://www.fairvalue-calculator.com/stock/HESTERBIO

Frequently asked questions

Is Hester Biosciences Limited (HESTERBIO) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of ₹2,009 versus a price of ₹2,306, about 13% lower (overvalued).
What is the fair value of HESTERBIO?
Our model-based fair value for Hester Biosciences Limited is ₹2,009 (as of Nov 14, 2026), built from audited fundamentals. The current price: ₹2,306.
What is the quality score of HESTERBIO?
Hester Biosciences Limited has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hester Biosciences Limited (HESTERBIO)?
Our model-based price target is the fair value of ₹2,009 (as of Nov 14, 2026) from 26 valuation models. Cautious scenario ₹1,062, optimistic scenario ₹3,114. It is a calculation from audited fundamentals, not an analyst target.
What is the Hester Biosciences Limited stock forecast for 2026?
Our models put fair value at ₹2,009, about 13% lower versus a price of ₹2,306 (overvalued). Cautious scenario ₹1,062, optimistic scenario ₹3,114. The calculation is refreshed regularly with new filings.
What is the revenue of Hester Biosciences Limited (HESTERBIO)?
Hester Biosciences Limited reported trailing-twelve-month revenue of about ₹3.3B (latest available figure, as of Nov 14, 2026).
Does Hester Biosciences Limited pay a dividend?
Hester Biosciences Limited currently shows a dividend yield of 0.48% relative to its recent price (as of Nov 14, 2026).
How much is the dividend of Hester Biosciences Limited (HESTERBIO) and when is the ex-dividend date?
Hester Biosciences Limited pays a dividend of ₹11.00 per share a year, a dividend yield of 0.5%. The last ex-dividend date was Jul 14, 2026. A dividend has been paid every year since at least 2015. The payout ratio is 6.8% of earnings. Free cash flow covers the dividend 4.46 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Hester Biosciences Limited (HESTERBIO)?
For today's price to be fair in a discounted-cash-flow model, Hester Biosciences Limited would have to grow free cash flow by 37.9 % per year for five years (discount rate 13.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 9.2 % per year. As of Nov 14, 2026.
What discount rate (WACC) does the fair value of HESTERBIO use?
Our models discount Hester Biosciences Limited at 13.9 %: a base by market capitalisation (micro), damped by beta 0.43, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hester Biosciences Limited that is +37.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.9 %) and the same formula as our fair value.
How much growth has Hester Biosciences Limited (HESTERBIO) delivered so far?
Over the past 5 years revenue at Hester Biosciences Limited grew 9.2 % a year. The price currently implies free-cash-flow growth of +37.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hester Biosciences Limited (HESTERBIO) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into Hester Biosciences Limited (+37.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hester Biosciences Limited (HESTERBIO)?
The free-cash-flow yield on the price is 2.20 %: that much free cash flow Hester Biosciences Limited produces per unit of market value. When it exceeds the discount rate of our models (13.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hester Biosciences Limited (HESTERBIO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hester Biosciences Limited it is ₹2,009 per share (as of Nov 14, 2026), against a price of ₹2,306. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Hester Biosciences Limited stock overvalued or undervalued in 2026?
As of Nov 14, 2026, HESTERBIO trades above its calculated fair value: price ₹2,306, fair value ₹2,009, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HESTERBIO?
No. The price is what the market pays today (₹2,306); the fair value is what the company's own numbers justify (₹2,009). For Hester Biosciences Limited the two are ₹297.04 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hester Biosciences Limited worth?
The market values Hester Biosciences Limited at about ₹21.1B (market capitalisation, as of Nov 14, 2026). Per share that is ₹2,306; our models calculate a fair value of ₹2,009 per share.
What do the bullish and bearish scenarios say about HESTERBIO?
Our models span a range for Hester Biosciences Limited: cautious scenario ₹1,062, base ₹2,009, optimistic ₹3,114 per share (as of Nov 14, 2026, price ₹2,306). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HESTERBIO?
Hester Biosciences Limited trades at a price-to-earnings ratio of 13.4 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹2,009 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings: 42.2. Other multiples: P/B 5.9, P/S 6.4, EV/EBITDA 27.7.
How solid is the balance sheet of Hester Biosciences Limited (HESTERBIO)?
Balance-sheet figures for Hester Biosciences Limited (as of Nov 14, 2026): return on equity 16.6%, debt of 0.25 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is HESTERBIO from its 52-week high?
Hester Biosciences Limited trades at ₹2,306, about 9% below its 52-week high of ₹2,534 and 84% above the low of ₹1,254 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹2,009 is for.
Which stocks are comparable to Hester Biosciences Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hester Biosciences Limited stock attractive at the current price?
The data as of Nov 14, 2026: price ₹2,306, calculated fair value ₹2,009 (−13%), Quality Score 64/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HESTERBIO calculated?
We run Hester Biosciences Limited through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹2,009 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Hester Biosciences Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hester Biosciences Limited (HESTERBIO)?
The closing price on Nov 16, 2026 was ₹2,306. Our model-based fair value is ₹2,009, about 13% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hester Biosciences Limited right now?
The model range is unusually wide (₹1,062 to ₹3,114). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Hester Biosciences Limited (HESTERBIO) come from?
Earnings per share at Hester Biosciences Limited grew 7.5 % a year from 2015 to 2026. Broken into its drivers: revenue per share +13.4 %, EBIT margin −4.1 %, tax rate −0.4 %, residual (interest, one-offs) −0.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Hester Biosciences Limited

How large is the market capitalisation of Hester Biosciences Limited (HESTERBIO)?
The market capitalisation of Hester Biosciences Limited is ₹21.1B (≈ $224M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hester Biosciences Limited (HESTERBIO)?
The price-to-sales ratio of Hester Biosciences Limited is 6.44 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hester Biosciences Limited (HESTERBIO)?
Earnings per share at Hester Biosciences Limited are ₹160.95 (price ÷ EPS = P/E 13.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hester Biosciences Limited (HESTERBIO)?
The dividend yield of Hester Biosciences Limited is 0.5% (payout 6.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hester Biosciences Limited (HESTERBIO)?
The net margin of Hester Biosciences Limited is 41.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hester Biosciences Limited (HESTERBIO)?
The return on equity (ROE) of Hester Biosciences Limited is 16.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hester Biosciences Limited (HESTERBIO)?
On an EBIT basis the return on assets of Hester Biosciences Limited is 10.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hester Biosciences Limited (HESTERBIO)?
The operating margin of Hester Biosciences Limited is 20.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hester Biosciences Limited (HESTERBIO)?
Revenue at Hester Biosciences Limited is down 8.2% versus a year earlier (3y avg +7.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hester Biosciences Limited (HESTERBIO)?
Earnings per share at Hester Biosciences Limited are growing 459% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Hester Biosciences Limited (HESTERBIO) carry?
The net debt of Hester Biosciences Limited is ₹1.9B (fiscal year 2026, ≈ 4.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Hester Biosciences Limited in the live analysis

One click puts Hester Biosciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.